MCSC specialists presented four studies at Euro Cancer 2026

News 09/30/2026

How to choose the optimal amount of surgery for cecum cancer? How are robotic interventions being improved? And is it possible to avoid immediate surgery with a complete response of the rectal tumor to treatment?

These issues became the topics of research by specialists of the MCSC named after A.S. Loginov, presented at the international summit Euro Cancer 2026.

On September 22, specialists of the MCSC Department of Coloproctology spoke at the III European Summit on Cancer Research and Oncology (3rd European Summit on Cancer Research and Oncologists), which was held on September 21-22 in Berlin. The Center's team joined the scientific program remotely and presented four oral reports on topical areas of colorectal cancer treatment.

The research team was represented by Vyacheslav Afandievich Aliyev, a leading researcher of the Department of Coloproctology, MD. Igor Vladimirovich Matveev, surgeon of the Department of Coloproctology, and graduate students Asker Notov, Nurlana Ismailova and Nadir Piriev made presentations.

• Igor Matveev presented the results of a study of ileocecal resection with extended lymph dissection in localized cecum cancer — a less extensive surgical intervention compared to standard right-sided hemicolectomy.
• Asker Notov spoke about the experience of robot-assisted colorectal surgery. The analysis of 55 operations showed how, with the accumulation of experience, the duration of the intervention and the connection time of the robotic system are reduced: Stabilization of these indicators was noted after 25-30 operations.
• Nurlana Ismailova's research was devoted to the Watch & Wait strategy, an organ—preserving approach for carefully selected patients with a complete clinical response after preoperative treatment of rectal cancer.
• Nadir Piriyev presented the results of the use of manual intracorporeal double-row anastomosis in minimally invasive right-sided hemicolectomy. There were no cases of anastomosis failure in the prospective group of 26 patients.

After the presentations, MCSC specialists answered the participants' questions and discussed the results with colleagues. The abstracts of all four studies are published in the collection of materials Euro Cancer 2026.

The presented works are united by a common task — to make the surgical treatment of colorectal cancer more personalized and safe, preserving the oncological effectiveness and quality of life of patients.